Spravato Overdosage

No cases of overdose were reported in clinical studies with Esketamine (Spravato). The potential for overdose of Esketamine (Spravato) by the patient is minimized due to the product's design and the administration taking place under the supervision of a healthcare professional (see Dosage & Administration).
Symptoms and signs: There is limited clinical trial experience with esketamine nasal spray doses higher than the maximum recommended dose of 84 mg. The maximum single esketamine nasal spray dose tested in healthy volunteers was 112 mg which showed no evidence of toxicity and/or adverse clinical outcomes. However, compared to the recommended dose range, the 112‑mg esketamine nasal spray dose was associated with higher rates of adverse reactions including dizziness, hyperhidrosis, somnolence, hypoesthesia, feeling abnormal, nausea and vomiting.
Treatment: There is no specific antidote for esketamine overdose. In the case of overdose, the possibility of multiple drug involvement should be considered. It is advisable to contact a poison control center to obtain the latest recommendations for the management of an overdose. Management of Esketamine (Spravato) overdose should consist of treating clinical symptoms and relevant monitoring. Close supervision and monitoring should continue until the patient recovers.